1109P Amivantamab vs real-world (RW) therapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC) epidermal growth factor receptor (EGFR) exon-20 insertion mutation (E20i)

Abstract

E20i, the 3rd most common EGFR mutation, is largely resistant to EGFR tyrosine kinase inhibitors (TKIs). In the single-arm CHRYSALIS study, aNSCLC E20i patients showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with activating and resistant EGFR mutations. This study compares the effectiveness of amivantamab to current systemic anti-cancer therapies in RW practice in Japan.